Clinical Cancer Research, Vol 4, Issue 5 1159-1164, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Phase I clinical trial of perillyl alcohol administered daily

GH Ripple, MN Gould, JA Stewart, KD Tutsch, RZ Arzoomanian, D Alberti, C Feierabend, M Pomplun, G Wilding and HH Bailey
University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA.

Perillyl alcohol (POH; NSC-641066), a naturally occurring monoterpene, has shown antitumor and preventive activity in preclinical studies in rodent models. Drug-related activities that have been observed include the induction of apoptosis, cell cycle arrest, the inhibition of posttranslational modification of proteins that are involved in signal transduction, and differential gene regulation. We treated 18 patients who had advanced malignancies with POH, which was given on a continuous three-times-a-day schedule at the following doses: (a) level 1 (L1), 800 mg/m2/dose; (b) level 2 (L2), 1600 mg/m2/dose; and (c) level 3 (L3), 2400 mg/m2/dose. The main toxicity, which seemed to be dose related, was gastrointestinal and included nausea and vomiting, anorexia, unpleasant taste, satiety, and eructation. Two heavily pretreated ovarian cancer patients experienced reversible > or =grade 3 granulocytopenia. Grade 1-2 fatigue was also noted. The parent drug was not detectable in the plasma. The mean peak plasma levels of the two main metabolites on days 1 and 29 were 175 and 139 microM (L1), 472 and 311 microM (L2), and 456 and 257 microM (L3) for perillic acid (PA) and 7.1 and 9.8 microM (L1), 34.2 and 34.0 microM (L2), and 26.2 and 23.4 microM (L3) for dihydroperillic acid (DHPA). Peak levels were noted 2-3 h postingestion for PA and 3-5 h postingestion for DHPA. Metabolite half-lives measured about 2 h for each. POH, PA, and DHPA were detectable in the urine of all patients at L3. About 9% of the total dose was recovered in the first 24 h. The majority was recovered as PA; less than 1% was recovered as POH. Disease stabilization for > or =6 months was seen, although no objective tumor responses were noted. Further study of POH continues with a more frequent dosing schedule.

This article has been cited by other articles:

				I. V. Lebedeva, Z.-z. Su, N. Vozhilla, L. Chatman, D. Sarkar, P. Dent, M. Athar, and P. B. Fisher Mechanism of In vitro Pancreatic Cancer Cell Growth Inhibition by Melanoma Differentiation-Associated Gene-7/Interleukin-24 and Perillyl Alcohol Cancer Res., September 15, 2008; 68(18): 7439 - 7447. [Abstract] [Full Text] [PDF]

				C. M. Berchtold, K.-S. Chen, S. Miyamoto, and M. N. Gould Perillyl Alcohol Inhibits a Calcium-Dependent Constitutive Nuclear Factor-{kappa}B Pathway Cancer Res., September 15, 2005; 65(18): 8558 - 8566. [Abstract] [Full Text] [PDF]

				V. Stearns, A. Coop, B. Singh, A. Gallagher, H. Yamauchi, R. Lieberman, M. Pennanen, B. Trock, D. F. Hayes, and M. J. Ellis A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia Clin. Cancer Res., November 15, 2004; 10(22): 7583 - 7591. [Abstract] [Full Text] [PDF]

				H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]

				D. Rajesh, R. A. Stenzel, and S. P. Howard Perillyl Alcohol as a Radio-/Chemosensitizer in Malignant Glioma J. Biol. Chem., September 19, 2003; 278(38): 35968 - 35978. [Abstract] [Full Text] [PDF]

				A. Wax, C. Yang, M. G. Muller, R. Nines, C. W. Boone, V. E. Steele, G. D. Stoner, R. R. Dasari, and M. S. Feld In Situ Detection of Neoplastic Transformation and Chemopreventive Effects in Rat Esophagus Epithelium Using Angle-resolved Low-coherence Interferometry Cancer Res., July 1, 2003; 63(13): 3556 - 3559. [Abstract] [Full Text] [PDF]

				W. Shi and M. N. Gould Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol Carcinogenesis, January 1, 2002; 23(1): 131 - 142. [Abstract] [Full Text] [PDF]

				A. Low-Baselli, W. W. Huber, M. Kafer, K. Bukowska, R. Schulte-Hermann, and B. Grasl-Kraupp Failure to demonstrate chemoprevention by the monoterpene perillyl alcohol during early rat hepatocarcinogenesis: a cautionary note Carcinogenesis, October 1, 2000; 21(10): 1869 - 1877. [Abstract] [Full Text] [PDF]

				G. H. Ripple, M. N. Gould, R. Z. Arzoomanian, D. Alberti, C. Feierabend, K. Simon, K. Binger, K. D. Tutsch, M. Pomplun, A. Wahamaki, et al. Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day Clin. Cancer Res., February 1, 2000; 6(2): 390 - 396. [Abstract] [Full Text]

				K. Singletary Diet, Natural Products and Cancer Chemoprevention J. Nutr., February 1, 2000; 130(2): 465 - 465. [Abstract] [Full Text]

				E. A. Ariazi, Y. Satomi, M. J. Ellis, J. D. Haag, W. Shi, C. A. Sattler, and M. N. Gould Activation of the Transforming Growth Factor {beta} Signaling Pathway and Induction of Cytostasis and Apoptosis in Mammary Carcinomas Treated with the Anticancer Agent Perillyl Alcohol Cancer Res., April 1, 1999; 59(8): 1917 - 1928. [Abstract] [Full Text] [PDF]